US 12,239,614 B2
Pharmacological prophylactics against stress-induced affective disorders in females
Christine Ann Denny, Ho-Ho-Kus, NJ (US); and Briana Kaying Chen, New York, NY (US)
Assigned to THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK, New York City, NY (US); and THE RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC., Menands, NY (US)
Filed by The Trustees of Columbia University in the City of New York, New York, NY (US); and The Research Foundation for Mental Hygiene, Inc., Menands, NY (US)
Filed on Sep. 28, 2022, as Appl. No. 17/954,864.
Application 17/954,864 is a continuation of application No. 16/761,338, granted, now 11,491,120, previously published as PCT/US2018/060082, filed on Nov. 9, 2018.
Claims priority of provisional application 62/583,774, filed on Nov. 9, 2017.
Prior Publication US 2023/0233485 A1, Jul. 27, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/135 (2006.01); A61P 25/24 (2006.01); A61K 9/00 (2006.01); A61K 45/06 (2006.01)
CPC A61K 31/135 (2013.01) [A61P 25/24 (2018.01); A61K 9/0019 (2013.01); A61K 9/0043 (2013.01); A61K 9/0053 (2013.01); A61K 45/06 (2013.01)] 20 Claims
 
1. A method for inducing and/or enhancing stress resilience in a female subject, comprising administering a pharmaceutic composition to the female subject prior to a stressor, wherein the pharmaceutic composition comprises an effective amount of an agent selected from the group consisting of (R)-ketamine, (S)-ketamine, (R,S)-ketamine, hydroxyketamines, dehydronorketamine, (R,S)-norketamine, (2R,6R)-hydroxynorketamine ((2R,6R)-HNK), and (2S,6S)-hydroxynorketamine, (2R,6R;2S,6S)-HNK, and a pharmaceutically acceptable salt thereof, wherein the effective amount of the agent administered to the female subject is no greater than 70% of an effective amount of the agent administered to a male subject.